Clinical evaluation of liver injury in patients with acute ischemic brain stroke treated with edaravone

Hepatology Research

Volumn 41, Issue 2, 2011, Pages 142-150

  Hirano, Masanori ^a  

^a Sangenjaya Hospital   (Japan)

Author keywords

Acute ischemic brain stroke; Edaravone; Etiologic factor; Liver injury; Renal disorder; Severe infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NORPHENAZONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN ISCHEMIA; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG WITHDRAWAL; EVALUATION; FEMALE; HUMAN; INCIDENCE; INJURY SEVERITY; KIDNEY DISEASE; LIVER CONGESTION; LIVER INJURY; LIVER ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 79251482177     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00751.x     Document Type: Article

References (13)

1. Yamamoto Y, Kuwahara T, Watanabe K, Watanabe K. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Report 1996; 2: 333-8.
2. Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998; 30: 575-8.
3. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988; 19: 480-5.
4. Houkin K, Nakayama N, Kamada K, Noujou T, Abe H, Kashiwaba T. Neuroprotective effect of the free radical scavenger MCI-186 in patients with cerebral infarction: clinical evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 1998; 7: 315-22.
5. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15: 222-9.
6. Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 2007; 11: 292-6.
7. Hishida A. Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. Clin Exp Nephrol 2009; 13: 118-22.
8. Takikawa H, Onji M, Takamori Y etal. A proposal of the diagnostic criteria of drug-induced liver injury by a workshop of DDW-J 2004. Kanzo 2005; 46: 85-90 (in Japanese).
9. Takikawa H, Onji M. A proposal of the diagnostic scale of drug induced liver injury. Hepatol Res 2005; 32: 250-1.
10. Guidance for industry: Drug-Induced Liver Injury. Premarketing clinical evaluation, FDA Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), July 2009.
11. Kimura K, Kazui S, Minematsu K, Yamaguchi T. Hospital-based prospective registration of acute ischemic stroke and transient ischemic attack in Japan. J Stroke Cerebrovasc Dis 2004; 13: 1-11.
12. Fukatsu T. Blood half-lives of AST, ALT, and γ-GTP. Nippon Iji Shinpo 2001; 4041: 90-1 (in Japanese).
13. For the appropriate use of Radicut Injection 30mg: Synopsis of status of accumulating important adverse reactions including multiple organ disorders. August 2009. Mitsubishi Tanabe Pharma Corporation (in Japanese).